What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
What Matricelf’s Parkinson’s spinout reveals about the future of cell based neurodegeneration therapies
Matricelf plans a subsidiary to commercialize its Parkinson’s therapy platform. Discover what this move signals for regenerative medicine and neurology innovation.